Long circulating nanoparticles for sustained release of therapeutic agents
View Patent ↗The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours.
1. A sterile, biocompatible, injectable nanoparticle composition comprising a plurality of long circulating nanoparticles having a diameter of about 70 to about 130 nm, each of the plurality of the long circulating nanoparticles comprising:
about 70 to about 90 weight percent poly(lactic)acid-co-poly(ethylene)glycol, wherein the weight ratio of poly(lactic)acid to poly(ethylene)glycol is about 15 kDa/2 kDa to about 20 kDa/10 kDa, and
a therapeutic agent encapsulated in the nanoparticles.
2. The sterile, biocompatible, injectable nanoparticle composition of claim 1 , wherein each of the plurality of nanoparticles comprise about 5 to about 25 weight percent therapeutic agent.
3. The sterile, biocompatible, injectable nanoparticle composition of claim 1 , wherein the weight ratio of poly(lactic)acid to poly(ethylene)glycol in each of the plurality of nanoparticles is about 15 kDa/4 kDa to about 20 kDa/6 kDa.
4. The sterile, biocompatible, injectable nanoparticle composition of claim 1 , wherein the weight ratio of poly(lactic)acid to poly(ethylene)glycol in each of the plurality of nanoparticles is about 16 kDa/5 kDa.
5. The sterile, biocompatible, injectable nanoparticle composition of claim 1 , wherein the composition is an aqueous solution further comprising a saccharide.
6. The sterile, biocompatible, injectable nanoparticle composition of claim 1 , further comprising a surfactant.
7. The sterile, biocompatible, injectable nanoparticle composition of claim 6 , wherein the surfactant is polysorbate 80.
8. The sterile, biocompatible, injectable nanoparticle composition of claim 1 , wherein therapeutic agent is a chemotherapeutic agent.
9. A sterile, biocompatible, injectable nanoparticle composition comprising a plurality of long circulating nanoparticles, each long circulating nanoparticle comprising:
about 70 to about 90 weight percent of an α-hydroxy polyester-co-polyether comprising a weight ratio of about 16/5 polylactic acid-polyethylene glycol, and docetaxel.
10. A method of treating a solid tumor cancer, comprising administering the nanoparticle composition of claim 1 , to a patient in need thereof.
11. The method of claim 10 , wherein at least 24 hours after administration, the solid tumor has a concentration of therapeutic agent at least about 20% more than a concentration of therapeutic agent in the tumor after administration of free therapeutic agent.